Sierra Oncology, Inc.
SRRADelisted Jul 1, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001290149
Sierra Oncology, Inc. was delisted on Jul 1, 2022; its insiders filed their last Form 4 on Jul 1, 2022; 109 institutions reported holding it in 13F filings for Q2 2022, worth $1.23B in total; no superinvestor held it.
Holders of 5% or more of SRRA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Sierra Oncology, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Sierra Oncology, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
31 Schedule 13D and 13G filings on Sierra Oncology, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 14, 2023 | Rock Springs Capital Management LP | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2023 | Versor Investments LP | 13G/AOld format | – | – | – | SEC |
| Jul 11, 2022 | Abingworth LLP | 13D/AOld format | – | – | – | SEC |
| Jul 5, 2022 | Vivo Capital IX, LLC | 13G/AOld format | – | – | – | SEC |
| May 6, 2022 | Longitude Capital Partners III, LLC | 13D/AOld format | – | – | – | SEC |
| Apr 22, 2022 | Versor Investments LP | 13GOld format | – | New | – | SEC |
| Mar 29, 2022 | Frazier Life Sciences Public Fund, L.P. | 13G/AOld format | – | – | – | SEC |
| Mar 21, 2022 | Abingworth LLP | 13D/AOld format | – | – | – | SEC |
| Mar 15, 2022 | OrbiMed Advisors LLC | 13D/AOld format | – | – | – | SEC |
| Feb 15, 2022 | Rock Springs Capital Management LP | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Venrock Healthcare Capital Partners II, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Caxton Corp | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | Vivo Capital IX, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | New Leaf Biopharma Opportunities I, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 10, 20224:55 PM ET | Gilead Sciences, Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2022 | Abingworth LLP | 13D/AOld format | – | – | – | SEC |
| Feb 10, 2022 | Adage Capital Partners GP, L.L.C. | 13G/AOld format | – | – | – | SEC |
| Feb 7, 2022 | PFM Health Sciences, LP | 13GOld format | – | New | – | SEC |
| Feb 4, 2022 | Longitude Capital Partners III, LLC | 13D/AOld format | – | – | – | SEC |
| Feb 2, 2022 | OrbiMed Advisors LLC | 13D/AOld format | – | – | – | SEC |
| Jan 28, 2022 | Frazier Life Sciences VIII, L.P. | 13G/AOld format | – | – | – | SEC |
| Nov 8, 2021 | Longitude Capital Partners III, LLC | 13D/AOld format | – | – | – | SEC |
| Nov 5, 2021 | Vivo Capital IX, LLC | 13G/AOld format | – | – | – | SEC |
| Nov 5, 2021 | OrbiMed Advisors LLC | 13D/AOld format | – | – | – | SEC |
| Nov 5, 2021 | Abingworth LLP | 13D/AOld format | – | – | – | SEC |
| Aug 16, 2021 | Frazier Life Sciences Public Fund, L.P. | 13GOld format | – | New | – | SEC |
| Apr 1, 2021 | Adage Capital Partners GP, L.L.C. | 13GOld format | – | New | – | SEC |
| Feb 16, 2021 | Rock Springs Capital Management LP | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Mangrove Partners Master Fund, Ltd. | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Mangrove Partners Master Fund, Ltd. | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Caxton Corp | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Sierra Oncology, Inc. shares.
No Form 144 notices for Sierra Oncology, Inc. are on file.